parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in sertoli cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 12817

CARMIL1 in dopamine neurons, braak+0.37 (p 0.334) → +0.21 (p 0.583)receipt 12824
CARMIL1 in astrocytes, braak+0.34 (p 0.375) → -0.56 (p 0.119)receipt 12823

receipt 12824: CARMIL1 in dopamine neurons, braak

power: full sample +0.29 (p 0.243, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.32 (p 0.198, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.346, n 18). could be the mix.
skeptic: leave-one-out range +0.21 to +0.45, sign flips 0; without severely affected donors +0.29 (p 0.243, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CARMIL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12823: CARMIL1 in astrocytes, braak

power: full sample -0.01 (p 0.976, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.807, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.01 (p 0.983, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.13, sign flips 7; without severely affected donors -0.01 (p 0.976, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CARMIL1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts